BioAge Labs BIOA 深 滬
已收盤 11-06 16:00:00 美东时间
5.34
-0.200
-3.61%
華盛通- 最 高5.54
- 今 開5.31
- 成交量 68.36万股
- 最 低 5.24
- 昨 收 5.54
- 總市值 2.45亿
- 52周最高 25.955
- 市盈率 靜 --
- 換手率 1.49%
- 52周最低 4.81
- 委 比 -99.86%
- 總股本 4589.69万
- 歷史最高 26.62
- 量 比 0.94
- 振 幅 5.42%
- 歷史最低 0.156
- 每 手 1
- 風險率 5.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Bioage Labs Q3 EPS $(0.73) Misses $(0.59) Estimate, Sales $298.000K Miss $1.644M Estimate
Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.59) by 23.73 percent. This is a 30.36 percent decrease over losses of $(0.56) per share from the same period last year. The company reported quarterly sales of $298.000 thousan...
11-06 05:56
BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates
BioAge Labs announced updates on their lead compound BGE-102, a potential best-in-class oral NLRP3 inhibitor, with Phase 2 trials in diabetic macular edema (QUELL-DME) and cardiovascular disease (QUELL-CV) progressing. Topline results for QUELL-DME are expected in H2 2027, while QUELL-CV data is anticipated in Q4 2026. The company also advanced its APJ agonist program for obesity, targeting IND submission by year-end 2026. BioAge reported a net l...
11-05 21:30
美股大行评级 | 潜在涨幅386.16%！摩根士丹利维持TeraWulf"超配"评级，上调目标价至65美元
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从62.5美元升至65美元；摩根士丹利：维持Hut 8"超配"评级，目标价从273美元升至275美元
10-13 12:30
UBS Initiates Coverage On Bioage Labs with Neutral Rating, Announces Price Target of $8
UBS analyst Alice Nettleton initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Neutral rating and announces Price Target of $8.
10-12 21:35
BioAge Labs initiates Phase 2 trial for BGE-102
BioAge Labs, Inc. ( ($BIOA) ) just unveiled an update. BioAge Labs announced th...
10-03 04:54
BioAge Labs to Present at Upcoming Investor Conferences
BioAge Labs, Inc. announced its participation in two upcoming investor conferences: the ROTH Healthcare Opportunities Conference in New York on September 29, 2026, and the Stifel Virtual Cardiometabolic Forum on September 30, 2026. Key executives, including BJ Sullivan, Dov Goldstein, MD, and Alexis Jakubowski, will engage in one-on-one meetings and a fireside chat. BioAge, a clinical-stage biopharmaceutical company, is developing therapeutic can...
09-25 20:30
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target
BTIG analyst Thomas Shrader reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $40 price target.
09-08 23:25
BioAge Labs Doses First Patient In Its Phsae 2 Study Of BGE-102 To Treat Diabetic Macular Edema
BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge" or the "Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the first participant has been dosed in QUELL-DME, a randomize...
09-08 20:06
